When January 27, 2022
10:00 AM - 12:00 PM
Location Remote via Zoom
Spaces left 45
Presentation:
Contingency Management (CM) is the best-researched, most effective -- yet least utilized -- treatment innovation in addiction. After a half-century of research, clinicians still have numerous concerns: ethics (is it enabling to pay patients money?), resources (where will the money come from?), testing (frequent and visually witnessed drug testing?), & management (who will do the intricate accounting?).
Technology can surmount each of these obstacles, with the added plus of patient engagement & relapse/dropout prediction. Providers will describe technology's potential for enhancing motivation, improving MAT adherence, & extending treatment retention.
Data from thousands of patient events with several different technologic tools indicates that these approaches are feasible with many types of: Substance use disorders (from tobacco smoking to opioids) Subpopulations (from pregnant women to criminal justice-involved returning citizens to corporate executives) Providers (from counselors to case managers to recovery coaches), and Settings (from medical centers to recovery homes to national insurance companies). Finally, large data (e.g., >90,000 financial transaction events from 1,400 patients) can generate imminent dropout and relapse indicators with good validity (e.g., 70% positive predictive value) that can be used to issue real-time alerts to providers to intervene -- even prior to a patient's return to drug use, allowing rapid treatment intensification without the need for repeat detoxification to address withdrawal.
Impacts range from decreased drinking, to longer treatment retention to meaningful program completion (e.g., improving graduation rates from 67% to 87% within a justice-system involved long-term rehabilitation).
Attendees will workshop how to achieve practical implementation within busy, oversubscribed and scarcely-resourced practices and treatment programs in the midst of an epidemic.
As a result of attending this training, participants will be able to:
Describe the research foundation for enhancing treatment outcomes in patients with substance use disorders using contingency management.
Explain the obstacles that have prevented wide-spread adoption of contingency management in routine care.
Analyze the utility of various new technologies that have been proposed and implemented to overcome the obstacles to adoption of contingency management.
PRESENTER:
Dr. Gastfriend is an addiction psychiatrist. At Harvard Medical School, he directed addiction research at Massachusetts General Hospital and was an investigator in the NIDA Cocaine Collaborative Study, NIAAA’s COMBINE Study and NIDA’s Clinical Trials Network. As Vice President at Alkermes, Inc., he directed scientific publications on Vivitrol in clinical, criminal justice and health economics research.
His research led most states to endorse the American Society of Addiction Medicine (ASAM) Criteria. His 150 scientific publications include the books The ASAM Criteria and Addiction Treatment Matching. His ASAM CONTINUUM – The ASAM Criteria Decision Engine® and ASAM’s CO-Triage® tools are being adopted nationwide.
In 2016, he co-founded DynamiCare Health, a nationally-scalable technology for Contingency Management and predictive analytics, winning awards from Harvard Business School, the Commonwealth of Massachusetts, the Governor of Ohio, and the New York Times. He has consulted to governments in Belgium, China, Iceland, Israel, Norway, Russia and the U.S.
Fee: $40; *NBCC add $5.
For registration information contact: 603-225-7060; training@nhadaca.org.